AVI BioPharma to Present at 28th Annual Westergaard SmallCap Conference.PORTLAND, Ore. -- AVI BioPharma, Inc. (Nasdaq:AVII) today announced that Denis R. Burger, Ph.D., chief executive officer of AVI, will be presenting at the Westergaard SmallCap Conference, sponsored by the Paulson Investment Company, Inc., on Monday, Nov. 21, 2005, at the Waldorf-Astoria Hotel in New York City New York City: see New York, city. New York City City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S. . Burger's presentation will take place in the Metropolitan East conference room from 9:40-10:05 a.m. EST EST electroshock therapy. EST abbr. electroshock therapy . Financial and Clinical Updates As of Monday, Nov. 14, 2005, AVI had raised $22.6 million in a direct equity placement with several institutional investors. AVI's cash position now stands at over $50 million, ensuring the company's continued progress with its clinical drug development programs. AVI recently announced the initiation of a Phase II clinical study called APPRAISAL, which is designed to evaluate AVI's Resten-MP(TM) antisense drug in the prevention of cardiovascular restenosis when delivered in conjunction with the placement of one or more bare-metal stents. Additional information about APPRAISAL was presented last month at the Transcatheter Cardiovascular Therapeutics conference in Washington, D.C. As part of AVI's continued efforts in antiviral drug development, the company announced in September the initiation of a multicenter exploratory safety and efficacy clinical trial in healthy volunteers and patients with chronic active hepatitis chronic active hepatitis 1. Obsolete term. See Chronic hepatitis2. Chronic viral hepatitis C virus (HCV HCV abbr. hepatitis C virus HCV 1 Hepatitis C virus, see there 2. Human coronavirus. See Coronavirus. ) infection. The HCV trial will assess the safety, tolerability, pharmacokinetics and viral response to AVI's NEUGENE(R) compound AVI-4065. About AVI BioPharma AVI BioPharma develops therapeutic products for the treatment of life-threatening diseases using third-generation NEUGENE antisense drugs. AVI's lead NEUGENE antisense compound is designed to target cell proliferation disorders, including cardiovascular restenosis, cancer and polycystic kidney disease Polycystic Kidney Disease Definition Polycystic kidney disease (PKD) is one of the most common of all life-threatening human genetic disorders. . In addition to targeting specific genes in the body, AVI's antiviral program uses NEUGENE antisense compounds to combat disease by targeting single-stranded RNA viruses, including West Nile virus West Nile virus, microorganism and the infection resulting from it, which typically produces no symptoms or a flulike condition. The virus is a flavivirus and is related to a number of viruses that cause encephalitis. , hepatitis C virus
"Safe Harbor" Statement under the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995: The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company's Securities and Exchange Commission filings. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion